Lilly Begins Building Third China Plant For Making Insulin For Diabetes
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly has begun construction on a plant in China for producing insulin, the U.S. company's third in the country as it expands operations to keep up with an enlarging market for diabetes treatments.